Areas Of High Disease Burden Research Articles

Quality ofChronic Disease (Diabetes & Hypertension) Care in Health Care Facilities in High Disease Burden Areas in Sidama Region: Cross-Sectional Study.

Diabetes and hypertension are major synergistic risk factors for microvasculopathy, microangiopathy, and neuropathy problems among patients with chronic disorder. Control of hypertension and diabetes have significant value in delaying these complications. The key for delaying complications in diabetes and hypertension is the quality of care. This study explored the quality ofdiabetes-hypertension care in health care facilities with high disease burden in Sidama region. An institution-based cross-sectional study was carried out. Patients with diabetes and hypertension were included in the study. In this study, we included 844 patients were included in the study. For data collection, the application software Kobo Collect was utilized. For data analysis, SPSS version 25 was used. Logistic regression was used to identify factors associated with quality of care. To measure quality, we employed patient outcome indicators focusing on long-term complications of the eye, heart, fasting blood pressure, and neuropathic complications. Ethical approval clearance was obtained from Hawassa University, College of Medicine and Health Sciences ethical review board. The mean age of patients was 47.99 ± 15.26 years, with a range of 18-90 years, while men make up 62% of the overall number of respondents. In terms of marital status, 700 (82.9%) were married. Concerning place of residence; 433 (51.3%) were from rural area. The primary diagnosis is diabetes for 419 (49.6%) patients, and nearly 23% of patients have both diabetes and hypertension. In terms of blood pressure, the average systolic pressure was 129.6 mmHg and the average diastolic pressure was 82.6 mmHg. Among the study participants, 391 (46.33%) patients received poor quality of chronic disease care. Patients living alone, patients who have professional work, fasting blood glucose in normal range, patients with higher education, and patients with serum creatinine receive relatively good chronic illness care.

Quality of Chronic Disease (Diabetes & Hypertension) Care in Health Care Facilities in High Disease Burden Areas in Sidama Region: Cross-Sectional Study [Letter

Quality of Chronic Disease (Diabetes & Hypertension) Care in Health Care Facilities in High Disease Burden Areas in Sidama Region: Cross-Sectional Study [Letter

The geographic diversity of authorship in leading general surgery journals; A study of 24,332 authors

BackgroundResearch guides evidence-based general surgery practice, advocacy, policy and resource allocation, but is seemingly lacking representation from those countries with greatest disease burden and mortality. Accordingly, we conducted a geographic study of publications in the most impactful general surgery journals worldwide. MethodsThe six general surgery journals with the highest 2020 impact factors were selected. Only journals specific to general surgery were included. For all original articles over the past five years, the affiliated country and city were extracted for the first, second and last author. Number of publications were adjusted per capita, and compared to Human Development Index (HDI) using logistic regression. Results8274 original articles were published in the top six ranked general surgery journals over 2016–2020, with 24,332 affiliated authors. Authors were most commonly associated with the US (27.88%), Japan (9.09%) and China (8.46%), or per capita, The Netherlands, Sweden and Singapore. There is a linear association between publishing in a top six journal and HDI of country of affiliation. Just four publications were from medium or low HDI countries over the period. ConclusionAuthorship in leading general surgery journals is predominantly from wealthy, Western countries. Authorship is associated with affiliation with a high HDI country, with few authors from medium or low HDI countries. There is a lack of representation in literature from Africa, Russia, and parts of Southeast Asia, and thus a lack of locally relevant evidence to guide surgical practice in these areas of high disease burden and low life expectancy.

Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial

In this prospective phase 2 trial, we investigated the toxicity and patient-reported quality-of-life outcomes in patients treated with stereotactic body radiation therapy (SBRT) to the prostate gland and a simultaneous focal boost to magnetic resonance imaging (MRI)-identified intraprostatic lesions while also de-escalating dose to the adjacent organs at risk. Eligible patients included low- or intermediate-risk prostate cancer (Gleason score ≤7, prostate specific antigen ≤20, T stage ≤2b). SBRT was prescribed to 40 Gy in 5 fractions delivered every other day to the prostate, with any areas of high disease burden (MRI-identified prostate imaging reporting and data system 4 or 5 lesions) simultaneously escalated to 42.5 to 45 Gy and areas overlapping organs at risk (within 2 mm of urethra, rectum, and bladder) constrained to 36.25 Gy (n=100). Patients without a pretreatment MRI or without MRI-identified lesions were treated to dose of 37.5 Gy with no focal boost (n=14). From 2015 to 2022, a total of 114 patients were enrolled with a median follow-up of 42 months. No acute or late grade 3+ gastrointestinal (GI) toxicity was observed. One patient developed late grade 3 genitourinary (GU) toxicity at 16 months. In patients treated with focal boost (n=100), acute grade 2 GU and GI toxicity was seen in 38% and 4% of patients, respectively. Cumulative late grade 2+ GU and GI toxicities at 24 months were 13% and 5% respectively. Patient-reported outcomes showed no significant long-term change from baseline in urinary, bowel, hormonal, or sexual quality-of-life scores after treatment. SBRT to a dose of 40 Gy to the prostate gland with a simultaneous focal boost up to 45 Gy is well tolerated with similar rates of acute and late grade 2+ GI and GU toxicity as seen in other SBRT regimens without intraprostatic boost. Moreover, no significant long-term changes were seen in patient-reported urinary, bowel, or sexual outcomes from pretreatment baseline.

Toxicity and Patient Reported Quality of Life Outcomes Following Prostate SBRT with Focal Boost to MRI Identified Prostate Cancer Lesions: Results of a Phase II Trial

<h3>Purpose/Objective(s)</h3> A focused boost to MRI identified prostate cancer lesions treated with radiotherapy has been shown to improve biochemical disease control without increased toxicity in standard fractionated radiation treatment. Prostate cancer is known to be sensitive to higher radiation doses per fraction and thus stereotactic body radiotherapy (SBRT) has become an increasingly popular treatment method. In this prospective phase II trial, we investigated the toxicity and patient reported quality of life outcomes in patients treated with SBRT to the prostate gland and a simultaneous focal boost to MRI identified intraprostatic lesions while also de-escalating dose to the adjacent organs at risk. <h3>Materials/Methods</h3> Eligible patients included low- or intermediate- risk prostate cancer (Gleason score ≤ 7, PSA ≤20, T stage ≤2b). SBRT was prescribed to 40 Gy in 5 fractions delivered every other day to the prostate, with areas of high disease burden (MRI-identified PI-RADS 4 or 5 lesions) escalated to 42.5-45 Gy and areas overlapping organs at risk (within 2 mm of urethra, anterior rectal wall, and bladder base) constrained to 36.25 Gy (n=98). Patients without a pre-treatment MRI were treated to dose of 37.5 Gy with no focal boost (n=14). Acute and late toxicity were graded using RTOG modified toxicity scales. Patient-reported outcome and quality of life was assessed using the AUA-IPSS lower urinary tract symptom score, IIEF-5 erectile function, and EPIC-26 surveys. Statistical testing was performed in statistical software. <h3>Results</h3> From 2015 to 2022, a total of 112 patients were enrolled with a median follow-up of 36 months. No acute or late grade 3+ GI or GU toxicity was observed. Within the focal boost arm, acute grade 2 GU toxicity during treatment or at 6-week follow-up was seen in 26% of patients. Acute grade 2 GI toxicity was seen in 1 patient. Cumulative late grade 2 GU toxicity was 8%. Rate of alpha blocker medication use following treatment was 26%. Cumulative late grade 2 GI toxicity was 2.3%. Patient reported outcomes showed no significant changes from baseline IPSS lower urinary tract, IIEF erectile function, or EPIC-26 urinary incontinence, urinary irritative, gastrointestinal, or sexual domain quality of life scores following treatment (p >0.05 for all tests via RANOVA). Two patients have had a biochemical recurrence to date, at 42 months and 60 months post treatment. <h3>Conclusion</h3> SBRT to a dose of 40 Gy to the prostate gland with a focal boost up to 45 Gy is well tolerated with no observed grade 3 toxicity and similar rates of acute and late grade 2 GI and GU toxicity as seen in other SBRT regimens without intraprostatic dose boost. Moreover, no significant changes were seen in patient reported urinary, bowel, or sexual outcomes from pre-treatment baseline at any follow-up date. Biochemical control data continue to mature but few treatment failures have been observed to date.

Institutional investors’ sustainability policies and the outcomes for the healthcare sector portfolios

The article reviews policies with respect to responsible investment in health as well as actual portfolio holdings in drug development firms by five large public pension funds in the US, Japan, Norway, the Netherlands and Canada. In spite of commitment to “sustainable corporate value”, no discernible tilt towards companies conducting research in the areas of high disease burden and unmet medical need is observed. Rather investments very closely track the size (market capitalisation) of the portfolio firms. A representative drug development company in portfolios of large public pension funds is constructed by taking a weighted average of product track records of individual companies included in those portfolios. The weights are based on the share of the fund's portfolio allocated to individual companies. According to this calculation, only 1 in 10 new medicines brought to the market by a representative drug development company makes a substantial contribution to illnesses they target compared to the existing treatments. Nevertheless, developing and sharing best practices for sustainable investment is a relatively new agenda pursued by large public and quasi-public asset owners worldwide, which presents an opportunity for the medical research community to contribute to meaningful guidelines for responsible evidence-based investment into commercial medical research.

Real-time Malaria Parasite Screening in Thick Blood Smears for Low-Resource Setting.

Malaria is a serious public health problem in many parts of the world. Early diagnosis and prompt effective treatment are required to avoid anemia, organ failure, and malaria-associated deaths. Microscopic analysis of blood samples is the preferred method for diagnosis. However, manual microscopic examination is very laborious and requires skilled health personnel of which there is a critical shortage in the developing world such as in sub-Saharan Africa. Critical shortages of trained health personnel and the inability to cope with the workload to examine malaria slides are among the main limitations of malaria microscopy especially in low-resource and high disease burden areas. We present a low-cost alternative and complementary solution for rapid malaria screening for low resource settings to potentially reduce the dependence on manual microscopic examination. We develop an image processing pipeline using a modified YOLOv3 detection algorithm to run in real time on low-cost devices. We test the performance of our solution on two datasets. In the dataset collected using a microscope camera, our model achieved 99.07% accuracy and 97.46% accuracy on the dataset collected using a mobile phone camera. While the mean average precision of our model is on par with human experts at an object level, we are several orders of magnitude faster than human experts as we can detect parasites in images as well as videos in real time.

The Arts and Tools for Using Routine Health Data to Establish HIV High Burden Areas: The Pilot Case of KwaZulu-Natal South Africa.

Background: To optimally allocate limited health resources in responding to the HIV epidemic, South Africa has undertaken to generate local epidemiological profiles identifying high disease burden areas. Central to achieving this, is the need for readily available quality health data linked to both large and small geographic areas. South Africa has relied on national population-based surveys: the Household HIV Survey and the National Antenatal Sentinel HIV and Syphilis Prevalence Survey (ANC) amongst others for such data for informing policy decisions. However, these surveys are conducted approximately every 2 and 3 years creating a gap in data and evidence required for policy. At subnational levels, timely decisions are required with frequent course corrections in the interim. Routinely collected HIV testing data at public health facilities have the potential to provide this much needed information, as a proxy measure of HIV prevalence in the population, when survey data is not available. The South African District health information system (DHIS) contains aggregated routine health data from public health facilities which is used in this article.Methods: Using spatial interpolation methods we combine three “types” of data: (1) 2015 gridded high-resolution population data, (2) age-structure data as defined in South Africa mid-year population estimates, 2015; and (3) georeferenced health facilities HIV-testing data from DHIS for individuals (15–49 years old) who tested in health care facilities in the district in 2015 to delineate high HIV disease burden areas using density surface of either HIV positivity and/or number of people living with HIV (PLHIV). For validation, we extracted interpolated values at the facility locations and compared with the real observed values calculating the residuals. Lower residuals means the Inverse Weighted Distance (IDW) interpolator provided reliable prediction at unknown locations. Results were adjusted to provincial published HIV estimates and aggregated to municipalities. Uncertainty measures map at municipalities is provided. Data on major cities and roads networks was only included for orientation and better visualization of the high burden areas.Results: Results shows the HIV burden at local municipality level, with high disease burden in municipalities in eThekwini, iLembe and uMngundgudlovu; and around major cities and national routes.Conclusion: The methods provide accurate estimates of the local HIV burden at the municipality level. Areas with high population density have high numbers of PLHIV. The analysis puts into the hand of decision makers a tool that they can use to generate evidence for HIV programming. The method allows decision makers to routinely update and use facility level data in understanding the local epidemic.

Insights from mathematical modelling on the proposed WHO 2030 goals for scabies.

Scabies was adopted by the World Health Organization (WHO) as a Neglected Tropical Disease in 2017. There is currently no formal global scabies control programmes or existing WHO guidelines on scabies control although at least two countries, Fiji and Ethiopia, have adopted national approaches to scabies control. In February 2019 WHO held a first Informal Consultation on a Framework for Scabies Control, in part as a response to multiple national requests for guidance on public health management in high disease burden areas. Below we outline control strategies proposed at this meeting and summarise the role that modelling can play in supporting the development of evidence to translate these proposals into formal WHO recommendations and national and global control programmes. Provisional proposals discussed at the WHO Informal Consultation for a scabies control programme include the use of mass drug administration when the community prevalence of scabies is ≥ 10% (generally considered to reflect a childhood prevalence of at least 20%) and the use of intensified case management when the prevalence is below 10%.

Direct detection of bacteremia by exploiting host-pathogen interactions of lipoteichoic acid and lipopolysaccharide

Bacteremia is a leading cause of death in sub-Saharan Africa where childhood mortality rates are the highest in the world. The early diagnosis of bacteremia and initiation of treatment saves lives, especially in high-disease burden areas. However, diagnosing bacteremia is challenging for clinicians, especially in children presenting with co-infections such as malaria and HIV. There is an urgent need for a rapid method for detecting bacteremia in pediatric patients with co-morbidities to inform treatment. In this manuscript, we have developed and clinically validated a novel method for the direct detection of amphiphilic pathogen biomarkers indicative of bacteremia, directly in aqueous blood, by mimicking innate immune recognition. Specifically, we have exploited the interaction of amphiphilic pathogen biomarkers such as lipopolysaccharides (LPS) from Gram-negative bacteria and lipoteichoic acids (LTA) from Gram-positive bacteria with host lipoprotein carriers in blood, in order to develop two tailored assays – lipoprotein capture and membrane insertion – for their direct detection. Our assays demonstrate a sensitivity of detection of 4 ng/mL for LPS and 2 ng/mL for LTA using a waveguide-based optical biosensor platform that was developed at LANL. In this manuscript, we also demonstrate the application of these methods for the detection of LPS in serum from pediatric patients with invasive Salmonella Typhimurium bacteremia (n = 7) and those with Staphylococcal bacteremia (n = 7) with 100% correlation with confirmatory culture. Taken together, these results demonstrate the significance of biochemistry in both our understanding of host-pathogen biology, and development of assay methodology, as well as demonstrate a potential new approach for the rapid, sensitive and accurate diagnosis of bacteremia at the point of need.

Spatial overlaps in the distribution of HIV/AIDS and malaria in Zimbabwe

BackgroundIn most developing economies particularly in Africa, more people are likely to die of HIV/AIDS and malaria compared to other diseases. HIV/AIDS tends to be superimposed on the long standing malaria burden particularly in sub-Saharan Africa. The detection and understanding of spatial overlaps in disease occurrence is important for integrated and targeted disease control. Integrated disease control can enhance efficiency and cost-effectiveness through the development of drugs targeting multiple infections in the same geographic space.MethodsUsing Zimbabwe as a case study, this study tests the hypothesis that malaria clusters coincide with HIV/AIDS clusters in space. Case data for the two diseases were obtained from the Ministry of Health and Child Care in Zimbabwe at district level via the District Health Information System (DHIS). Kulldorff’s spatial scan statistic was used to test for spatial overlaps in clusters of high cases of HIV/AIDS and malaria at district level. The spatial scan test was used to identify areas with higher cases of HIV/AIDS and malaria than would be expected under spatial randomness.ResultsResults of this study indicate that primary clusters of HIV/AIDS and malaria were not spatially coincident in Zimbabwe. While no spatial overlaps were detected between primary clusters of the two diseases, spatial overlaps were detected among statistically significant secondary clusters of HIV/AIDS and malaria. Spatial overlaps between HIV/AIDS and malaria occurred in five districts in the northern and eastern regions of Zimbabwe. In addition, findings of this study indicate that HIV/AIDS is more widespread in Zimbabwe compared to malaria.ConclusionsThe results of this study may therefore be used as a basis for spatially-targeted control of HIV/AIDS and malaria particularly in high disease burden areas. This is important as previous interventions have targeted the two diseases separately. Thus, targeted control could assist in resource allocation through prioritising areas in greatest need hence maximising the impact of disease control.

Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care: 1997–2001

Objectives To describe recent federal sponsorship of cost-effectiveness and related health economics research to provide insight into the functioning of existing research support systems and assess the roles of federal health agencies. Methods Using the PubMed database, we identified cost-effectiveness and related publications citing support from a US government entity and published during the period of 1997 through 2001, and audited them for information on funding sources, study type, and content focus. Results Five Department of Health and Human Services agencies and centers and the Veterans Administration are cited as funders in 74% of 520 federally supported health economics publications we identified. Three-fourths of federally supported publications address five areas of high disease burden: infections, cancer, HIV/AIDS, cardiovascular disease, and substance abuse. Other high burden diseases, including mental health, diabetes, and injuries, receive less attention. Federal support of health economics studies of health education and care delivery—intervention types underexamined in the field—is relatively strong but most often focuses on substance abuse or mental health services. Each of the top federal funders has a distinct funding pattern, but there are substantial areas of overlap within which we could not identify content domains specific to one funder or another. Conclusions Federal support of health economics research has paralleled growth in the field. Federal funders support projects consistent with their mission and focus on high-burden disease areas. However, overlapping funding areas, ambiguity concerning agency interests within overlapping content areas, and gaps in some disease and intervention areas suggest that the coordination of health economics research funding could be improved.